Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
NCT05649059
Recruiting
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/16/2025
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Phobia, Social
Register for Updates
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
NCT05010005
Recruiting
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Register for Updates
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03113643
Recruiting
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
Mindfulness Intervention for Fibromyalgia Delivered Through a Smartphone App
NCT07032519
Recruiting
The purpose of this pilot feasibility study is to evaluate the effects of a smartphone-based mindfulness intervention (MBI) on pain-related outcomes in individuals with fibromyalgia. This 8-week randomized controlled trial will compare an MBI app group to a control group who completes assessments only through the app. The MBI intervention includes weekly video content focused on mindfulness practice and psychoeducation, combined with daily symptom tracking through the app. Participants in both... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/15/2025
Locations: The Brigham and Women's Hospital Department of Anesthesiology, Boston, Massachusetts
Conditions: Fibromyalgia
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Dana Farber Cancer Institite, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates
Telehealth for Pain and Unhealthy Drinking Among PLWH
NCT05503173
Recruiting
This randomized controlled trial is a between-groups design to compare the Motivational and Cognitive Behavioral Management for Alcohol and Pain (MCBMAP) Intervention to a Brief Advice and Information Control condition. Two-hundred and fifty participants who have HIV with moderate or greater chronic pain will be randomized for the trial. Recruitment will take place through digital media. A unique feature of this intervention trial is that most of the procedures will be conducted remotely which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: Charles River Campus, Boston University, Psychology Department- remote study, Boston, Massachusetts
Conditions: HIV, Chronic Pain, Unhealthy Alcohol Use
Register for Updates
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
NCT07033208
Recruiting
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Crohn Disease, Inflammatory Bowel Diseases, Healthy
Register for Updates
EluPro Antibiotic-Eluting BioEnvelope Registry
NCT06854081
Recruiting
A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Cardiac Arrhythmias
Register for Updates
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Dana Farber/Harvard Cancer Center, Boston, Massachusetts
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Register for Updates
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
06/13/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Post-ligation Cardiac Syndrome
Register for Updates